KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities
Luchini C, Paolino G, Mattiolo P, Piredda M, Cavaliere A, Gaule M, Melisi D, Salvia R, Malleo G, Shin J, Cargnin S, Terrazzino S, Lawlor R, Milella M, Scarpa A. KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities. Journal Of Experimental & Clinical Cancer Research 2020, 39: 227. PMID: 33115526, PMCID: PMC7594413, DOI: 10.1186/s13046-020-01732-6.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaAnti-PD-1/PD-L1 agentsDefective DNA mismatch repairComprehensive molecular profilingMicrosatellite instabilityKinase fusion geneDetermination of KRASTherapeutic molecular targetsHistological diagnosisKRAS mutationsBRAF mutationsDuctal adenocarcinomaKinase inhibitorsTailored treatmentTumorMAPK inhibitorFusion geneGenetic landscapeMolecular targetsKRASDeadly diseaseDNA mismatch repairMolecular traits
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply